It's Cenobomate. SK will market in the USA while Arvelle will market ROW.
Do you guys remember when we were screaming about the opportunity this drug had for UCB back in 2015 but the goons in Braine kept saying it was a shit drug? Thanks Benoit Kenda, yet another great decision you advocated for.
